Asia Pacific Insulin Pens Market to 2027 - Regional Analysis and Forecasts by Product Type (Disposable and Reusable); Application (Diabetes Type-1 and Diabetes Type-2); Distribution Channel (Hospital Pharmacies, Retail Pharmacies and e-Commerce) and Geography

Report / Search Code: RnM3728044   Publish Date: 10 September, 2019

Price

<table>
<thead>
<tr>
<th>Description</th>
<th>1-user PDF: $ 3000.0</th>
<th>Site PDF: $ 4000.0</th>
<th>Enterprise PDF: $ 5000.0</th>
</tr>
</thead>
</table>

The Asia Pacific insulin pen market is expected to reach US$ 1,703.7 Mn in 2027 from US$ 743.4 Mn in 2018. The market is estimated to grow with a CAGR of 9.8% from 2019-2027. The growth of the insulin pen market is primarily attributed to the growing geriatric population, increasing rate of obesity and rising incidence of diabetes. However, availability of alternatives for drug delivery and limitations associated with insulin pens are likely to pose a negative impact on the market growth. On the other hand, development of cost efficient pen needles is likely to have a positive impact on the growth of the Asia Pacific insulin pen market in the coming years.

Diabetes is a life-threatening chronic disease with no specialized cure. It is mainly caused by the body’s inability to produce or effectively utilize the hormone insulin. This inability prevents the body from adequately regulating blood glucose levels. There are two types of diabetes namely diabetes type-I also known as diabetes insipidus and diabetes type-II also termed as diabetes mellitus. Incidences and prevalence of diabetes is steadily increasing across the globe. Type 2 diabetes is the most prevalent form of diabetes and has increased alongside cultural and societal changes. In high-income countries up to 91% of adults with the disease have type 2 diabetes.

According to the International Diabetes Federation estimated that there were 382 million people with diabetes in 2013, a number exceeding its earlier predictions. Here, more than 60% of the people with diabetes live in Asia, with almost one-half in China and India combined. The Western Pacific is the world’s most populous region, has more than 138.2 million people with diabetes, and the number may rise to 201.8 million by 2035.

<table>
<thead>
<tr>
<th>TABLE 1. PREVALENCE OF DIABETES WORLDWIDE, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Country</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>China</td>
</tr>
<tr>
<td>Japan</td>
</tr>
<tr>
<td>India</td>
</tr>
</tbody>
</table>

Source: International Diabetes Federation

Diabetes of all types can lead to various complications in many parts of the body and can increase the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss and nerve damage are the major complications associated with this disease.

Patients suffering from diabetes require frequent monitoring and external administration of insulin that is given through insulin pens and other medical devices. The rising prevalence of diabetes across the globe is expected to drive the growth of the insulin pens market worldwide during the forecast period.

In 2018, the disposable segment held a largest market share of 62.6% of the insulin pen market, by product. The disposable is expected to dominate its market share in 2027 owing to the rise in the prevalence of the diabetes and presence of the several market players that offers technically advanced products. The disposable segment is also anticipated to witness the fastest growth rate of 10% during the forecast period, 2019 to 2027.

Retail pharmacies segment a largest market share of 39.8% of the insulin pen market, by distribution channel in 2018. This segment is also expected to dominate the market in 2027 oving Chemists and retail pharmacies are considered to be the most preferred channel for patients using diabetes insulin pens. Retail pharmacies are among the most go-to places opted by the patients resulting in the high share and growth of the segment in the insulin pens market over the coming years. E-Commerce segment is also expected to grow at the fastest growth rate of 10.4% during the forecast period, 2019 to 2027.

Some of the major primary and secondary sources for insulin pen included in the report are, Owen Mumford, LTD., Novo Nordisk a/s, Companion Medical, Berlin-Chemie AG, Pendiq GmbH, Emperra GmbH E-Health Technologies, Eli lilly and company, Ypsomed Ag, SANOFI, Biocion, and others.

**Contents:**

**TABLE OF CONTENTS**

Part 1. Introduction

- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance

Part 2. North America Diabetes Care Devices Market – Key Takeaways


- 3.1 overview
- 3.2 market segmentation
  - 3.2.1 North America Diabetes Care Devices Market – By Product
  - 3.2.2 North America Diabetes Care Devices Market – By End USer
  - 3.2.3 North America Diabetes Care Devices Market – By Country
- 3.3 PEST Analysis

Part 4. North America Diabetes Care Devices Market - Key Market Dynamics

- 4.1 Key Market Drivers
  - 4.1.1 Growing Geriatric Population
  - 4.1.2 Rapid Technological Advancements in Diabetes Care Devices
4.2 Key Market Restraints
   - 4.2.1 High Cost of Diabetes Care Devices
   - 4.2.2 Risks Associated with the Insulin Delivery Devices
4.3 Key Market Opportunities
   - 4.3.1 Development of Cost Efficient Pen Needles
   - 4.4 Future Trends
   - 4.4.1 Growing Product Innovations
4.5 Impact Analysis

Part 5. Diabetes Care Devices Market – North America Analysis
   - 5.1 North America DIABETES CARE DEVICES market Revenue Forecasts and Analysis
   - 5.2 Market positioning
   - 5.3 PERFORMANCE OF KEY PLAYERS
     - 5.3.1 Medtronic
     - 5.3.2 F. Hoffmann-La Roche Ltd.

   - 6.1 Overview
   - 6.2 North America diabetes care devices Market BY Product, 2018 & 2027 (%)
   - 6.3 North America DIABETES CARE DEVICES market Revenue And Forecasts to 2027, By Product (US$ Mn)
     - 6.3.1 North America Glucose Monitoring Devices Market Revenue And Forecasts to 2027, By Type (US$ Mn)
     - 6.3.2 North America Insulin Delivery Devices Market Revenue And Forecasts to 2027, By Type (US$ Mn)
   - 6.4 Glucose Monitoring Devices Market
     - 6.4.1 Overview
     - 6.4.2 North America Glucose Monitoring Devices Market Revenue and Forecast to 2027 (US$ Mn)
     - 6.4.3 Glucometers Market
       - 6.4.3.1 Overview
     - 6.4.4 Lancets Market
       - 6.4.4.1 Overview
     - 6.4.5 Testing Strips Market
       - 6.4.5.1 Overview
     - 6.4.6 Other Glucose Monitoring Devices Market
       - 6.4.6.1 Overview
     - 6.4.6.2 North America Other Glucose Monitoring Devices Market Revenue and Forecast to 2027 (US$ Mn)
   - 6.5 Insulin Delivery Devices Market
     - 6.5.1 Overview
     - 6.5.2 North America Insulin Delivery Devices Market Revenue and Forecast to 2027 (US$ Mn)
     - 6.5.3 Insulin Pens Market
       - 6.5.3.1 Overview
     - 6.5.4 Insulin Syringes Market
       - 6.5.4.1 Overview
     - 6.5.5 Insulin Pumps Market
       - 6.5.5.1 Overview
     - 6.5.6 Other Insulin Delivery Devices Market
       - 6.5.6.1 Overview
     - 6.5.6.2 North America Insulin Delivery Devices Market Revenue and Forecast to 2027 (US$ Mn)

Part 7. North America Diabetes Care Devices Market Analysis – By End User
   - 7.1 Overview
   - 7.2 NORTH AMERICA DIABETES CARE DEVICES MARKET, BY End User, 2018 & 2027 (%)
   - 7.3 North America DIABETES CARE DEVICES market Revenue And Forecasts to 2027, By End User (US$ Mn)
     - 7.4 Homecare Market
       - 7.4.1 Overview
     - 7.4.2 North America Homecare Market Revenue and Forecasts to 2027 (US$ Mn)
     - 7.5 hospitals & Clinics Market
       - 7.5.1 Overview
       - 7.5.2 North America Hospitals & Clinics Market Revenue and Forecasts to 2027 (US$ Mn)

Part 8. North America Diabetes Care Devices Market Revenue And Forecasts To 2027
   - 8.1 Overview
   - 8.2 North America DIABETES CARE DEVICES market Revenue and Forecasts to 2027 (US$ Mn)
   - 8.3 North America DIABETES CARE DEVICES market Revenue And Forecasts to 2027, By Product (US$ Mn)
     - 8.3.1 North America Glucose Monitoring Devices Market Revenue And Forecasts to 2027, By Type (US$ Mn)
     - 8.3.2 North America Insulin Delivery Devices Market Revenue And Forecasts to 2027, By Type (US$ Mn)
   - 8.4 North America DIABETES CARE DEVICES market Revenue And Forecasts to 2027, By End User (US$ Mn)
   - 8.5 North America Diabetes care devices Market Revenue And Forecasts to 2027, By Country (%)
   - 8.6 US DIABETES CARE DEVICES market Revenue and Forecasts to 2027 (US$ Mn)
     - 8.6.1 US Diabetes Care Devices Market Revenue and Forecasts to 2027 (US$ Mn)
     - 8.6.2 US Diabetes Care Devices Market Revenue And Forecasts to 2027, By Product (US$ Mn)
       - 8.6.2.1 US Glucose Monitoring Devices Market Revenue And Forecasts to 2027, By Type (US$ Mn)
       - 8.6.2.2 US Insulin Delivery Devices Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.6.3 US Diabetes Care Devices Market Revenue And Forecasts to 2027, By End User (US$ Mn)

8.7 Canada Diabetes Care devices Market Revenue and Forecasts to 2027 (US$ Mn)
- 8.7.1 Canada Diabetes Care Devices Market Revenue and Forecasts to 2027 (US$ Mn)
- 8.7.2 Canada Diabetes Care Devices Market Revenue And Forecasts to 2027, By Product (US$ Mn)
  - 8.7.2.1 Canada Glucose Monitoring Devices Market Revenue And Forecasts to 2027, By Type (US$ Mn)
  - 8.7.2.2 Canada Insulin Delivery Devices Market Revenue And Forecasts to 2027, By Type (US$ Mn)
- 8.7.3 Canada Diabetes Care Devices Market Revenue And Forecasts to 2027, By End User (US$ Mn)

8.8 Mexico Diabetes care devices Market Revenue and Forecasts to 2027 (US$ Mn)
- 8.8.1 Mexico Diabetes Care Devices Market Revenue and Forecasts to 2027 (US$ Mn)
- 8.8.2 Mexico Diabetes Care Devices Market Revenue And Forecasts to 2027, By Product (US$ Mn)
  - 8.8.2.1 Mexico Glucose Monitoring Devices Market Revenue And Forecasts to 2027, By Type (US$ Mn)
  - 8.8.2.2 Mexico Insulin Delivery Devices Market Revenue And Forecasts to 2027, By Type (US$ Mn)
- 8.8.3 Mexico Diabetes Care Devices Market Revenue And Forecasts to 2027, By End User (US$ Mn)

- 9.1 Overview
- 9.2 Comparative Company Analysis
- 9.3 Growth Strategies done by the companies in the Market, (%)
- 9.4 Organic Developments
  - 9.4.1 Overview
- 9.5 Inorganic developments
  - 9.5.1 Overview

Part 10. Diabetes Care Devices Market – Key Company Profiles
- 10.1 BD
  - 10.1.1 Key Facts
  - 10.1.2 Business Description
  - 10.1.3 Financial Overview
  - 10.1.4 Product Portfolio
  - 10.1.5 SWOT Analysis
  - 10.1.6 Key Developments
- 10.2 Novo Nordisk a/s
  - 10.2.1 Key Facts
  - 10.2.2 Business Description
  - 10.2.3 Financial Overview
  - 10.2.4 Product Portfolio
  - 10.2.5 SWOT Analysis
  - 10.2.6 Key Developments
- 10.3 B. Braun Melsungen AG
  - 10.3.1 Key Facts
  - 10.3.2 Business Description
  - 10.3.3 Financial Overview
  - 10.3.4 Product Portfolio
  - 10.3.5 SWOT Analysis
  - 10.3.6 Key Developments
- 10.4 Medtronic
  - 10.4.1 Key Facts
  - 10.4.2 Business Description
  - 10.4.3 Financial Information
  - 10.4.4 Product Portfolio
  - 10.4.5 SWOT Analysis
  - 10.4.6 Key Developments
- 10.5 Tandem Diabetes Care, Inc.
  - 10.5.1 Key Facts
  - 10.5.2 Business Description
  - 10.5.3 Financial Information
  - 10.5.4 Product Portfolio
  - 10.5.5 SWOT Analysis
  - 10.5.6 Key Developments
- 10.6 Insulet Corporation
  - 10.6.1 Key Facts
  - 10.6.2 Business Description
  - 10.6.3 Financial Information
  - 10.6.4 Product Portfolio
  - 10.6.5 SWOT Analysis
  - 10.6.6 Key Developments
- 10.7 Eli Lilly and company
  - 10.7.1 Key Facts
  - 10.7.2 Business Description
  - 10.7.3 Financial Overview
  - 10.7.4 Product Portfolio
  - 10.7.5 SWOT Analysis
  - 10.7.6 Key Developments
- 10.8 Dexcom, Inc.
  - 10.8.1 Key Facts
  - 10.8.2 Business Description
  - 10.8.3 Financial Overview
  - 10.8.4 Product Portfolio
  - 10.8.5 SWOT Analysis
  - 10.8.6 Key Developments
- 10.9 Terumo Corporation
  - 10.9.1 Key Facts
  - 10.9.2 Business Description
10.9.3 Financial Overview
10.9.4 Product portfolio
10.9.5 SWOT ANALYSIS
10.9.6 KEY DEVELOPMENTS

10.10 F. Hoffmann-La Roche Ltd.
10.10.1 Key Facts
10.10.2 Business Description
10.10.3 Financial Overview
10.10.4 Product Portfolio
10.10.5 SWOT Analysis
10.10.6 Key Developments

Part 11. Appendix
11.1 About The Insight Partners
11.2 Glossary of Terms
11.3 Methodology
11.3.1 Coverage
11.3.2 Secondary Research
11.3.3 Primary Research